Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy

Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”

Torch light
• Source: Shutterstock (Shutterstock)

Targeted radiopharmaceuticals, which combine cancer-seeking ligands with radioactive isotopes to deliver precision radiation, are emerging as a new frontier of cancer care.

That’s the view of the dealmakers and investors driving a flurry of activity in the space: Bristol Myers Squibb Company’s $4.1bn acquisition of RayzeBio and Eli Lilly and Company’s $1

Promising data from Novartis AG’s flagship duo of marketed radiopharmaceuticals, Lutathera (lutetium 177 dotatate) and Pluvicto (lutetium 177 vipivotide tetraxetan), are fueling the hunt for next-generation approaches that build upon and expand this modality’s applications beyond rare neuroendocrine tumors

More from Innovation

More from In Vivo